FDA Clears Boston Scientific Bare Metal Rebel Coronary Stent System

Advanced BMS provides additional treatment option for interventional cardiologists and patients


July 22, 2014

Boston Scientific received U.S. Food and Drug Administration (FDA) approval for the Rebel platinum chromium coronary stent system, the company's latest-generation bare-metal stent for the treatment of coronary artery disease (CAD), in July 2014. Bare-metal stents continue to play an important role in the treatment of CAD and represent a significant portion of the global stent market. The company received CE mark for the Rebel stent in February 2014.

The Rebel expands the Boston Scientific family of stents featuring its proprietary platinum chromium (PtCr) alloy and a customized stent architecture design.  The stent offers the identical stent platform as the Promus Premier drug-eluting stent (DES) but without the everolimus drug.

The system features unparalleled visibility, low recoil, exceptional radial strength and fracture resistance, while improving axial strength and deliverability. Its enhanced low-profile delivery system also features a shorter, more visible tip, a dual-layer balloon and a Bi-Segment inner lumen catheter designed to facilitate precise stent delivery across challenging lesions.

The Rebel is offered in a matrix of 46 sizes, ranging in diameter from 2.25 mm to 4.50 mm and lengths of 8 mm to 32 mm on a Monorail platform. This provides physicians with a range of options designed to best suit patient needs.

For more information: www.bostonscientific.com